**Supplementary Table 2. Histology scores of hepatic injury in three groups**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Score** | **Control (G1)** | | **TAA (G2)** | | **TAA+SY (G3)** | | **G1 vs. G2** | **G1 vs. G3** | **G2 vs. G3** |
| **Mean** | **SD** | **Mean** | **SD** | **Mean** | **SD** | ***p*** | | |
| Inflammation | 0.00 | 0.00 | 2.29 | 0.83 | 1.55 | 0.69 | *<*0.001 | <0.001 | 0.024 |
| Ballooning | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.60 | n.s | n.s | n.s |
| Steatosis | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n.s | n.s | n.s |
| Fibrosis | 0.22 | 0.44 | 3.29 | 0.73 | 2.36 | 1.03 | <0.001 | <0.001 | 0.017 |

Hepatocyte ballooning (0 vs. 0 vs. 0.18) and steatosis (0 vs. 0 vs. 0) were not different among the three groups and lobular inflammation (0 vs. 2.29 vs. 1.55), and fibrosis grade (0.22 vs. 3.29 vs, 2.36) were decreased in the TAA-SY group compared with the TAA group (\**p*<0.05, \*\**p*<0.01, \*\*\**p*<0.001). n.s, not significant; TAA, thioacetamide-injected; TAA-SY, TAA-injected and silymarin-treated.